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Heterozygous mutations in CNTNAP2 have been identified in patients with a range of complex 
phenotypes including intellectual disability, autism and schizophrenia. However heterozygous 
CNTNAP2 mutations are also common in the normal population. Conversely, homozygous mutations 
are rare and have not been found in unaffected individuals.  
 
Case presentation 
We describe a consanguineous family carrying a deletion in CNTNAP2 predicted to abolish function of 
its protein product, CASPR2. Affected family members show epilepsy, facial dysmorphisms, severe 
intellectual disability and impaired language. We compared these patients with previously reported 




We propose that CASPR2 loss produces a syndrome involving early-onset refractory epilepsy, 
intellectual disability, language impairment and autistic features that can be recognized as CASPR2 
deficiency disorder. Further screening for homozygous patients meeting these criteria, together with 
detailed phenotypic investigations will be crucial for understanding the contribution of CNTNAP2 to 
normal and disrupted development. 
 
Keywords 
CNTNAP2, epilepsy, intellectual disability, language regression, autism 
  
. CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a





The CNTNAP2 gene (located on 7q35) is encoded by 24 exons, spanning 2.3 Mb, making it a 
large physical target for disruptive mutations. The majority of reported patients carry heterozygous 
disruptions of CNTNAP2 and usually display some combination of core phenotypes including 
intellectual disability (ID), seizures, autistic features and impaired language [1].  However, the 
phenotype associated with heterozygous CNTNAP2 mutation is complex as the severity of 
characteristics varies across patients, and in some cases additional phenotypes are observed (e.g. 
Tourette syndrome, schizophrenia). Furthermore, coding changes in a single copy of CNTNAP2 have 
also been found in unaffected individuals, suggesting heterozygous mutations are not always fully 
penetrant.  
CNTNAP2 encodes the CASPR2 protein - a member of the neurexin superfamily of proteins 
that facilitate cell-cell interactions [2] and form molecular bridges at synapses to influence synaptic 
strength and plasticity [3]. CASPR2 is a transmembrane protein with a small intracellular and a large 
extracellular component (see Figure 1) containing four laminin G domains and two epidermal growth 
factor-like (EGF-like) domains thought to be involved in receptor-ligand interactions, cell adhesion, 
migration and differentiation [4, 5]. Unlike most neurexin proteins, the CASPR2 extracellular region 
also contains a discoidin/neuropilin homology domain and a fibrinogen-like region which mediate 
cell-cell adhesions and extracellular matrix interactions [6]. 
CNTNAP2 is expressed across a number of brain regions throughout development and into 
adulthood (see [1] for review). In humans, CNTNAP2 is expressed in the cortex with enrichment in 
frontal and perisylvian regions, and in the striatum, thalamus and amygdala [7, 8]. This expression 
pattern recapitulates the cortico-striato-thalamic circuitry known to modulate higher order cognitive 
processes, including language, reward, and frontal executive function. In mouse models, CASPR2 
affects synaptic transmission and dendritic arborisation [9], and both mouse models and human 
patients have suggested that CNTNAP2 is important for normal cortical development [10]. Thus it is 
clear that CASPR2 plays an important role in brain development and function. 
 
MATERIALS AND METHODS 
Patients 
Ethical approval for this study was obtained by the Ethic Committee of the University of Bari, Italy. 
 
Genetic study 
Array-CGH (aCGH) was performed using the BlueGnome ISCA 4x44k Cytochip oligoarray. Copy 
number variants (CNVs) were identified using the BlueFuse multi v2.3 software (BlueGnome). Human 
genomic DNA was used as a positive control (Promega #G1471)[11]. A CNV was identified on 
chromosome 7. To confirm the deletion, DNA was extracted from blood samples of the affected sibs 
and family controls. PCR primers flanking the deletion were used to amplify DNA and determine the 
approximate deletion breakpoint. PCR was performed using Taq DNA polymerase kit (Invitrogen) as 
per supplier’s instructions.  Following this, a fragment spanning the breakpoint was amplified using 
the Advantage2 PCR kit (Clonetech, as per supplier’s instructions), using the following primers; Fwd: 
TCCGGTCTTGGCATTGGGAATCATTAGCC, Rev: TCAGCAGAGTGAAGAGACAACCCACAGAGT. This 
breakpoint spanning PCR yielded a 730bp product from homozygous and heterozygous DNA but not 




Herein, we report a consanguineous family carrying a deletion disrupting the coding region of 
CNTNAP2. Two affected female siblings (Patient 1 and 2) identified in this family were homozygous 
for the deletion (Figure 1). The affected sisters had one unaffected male sibling and their parents 
(first degree cousins) were also unaffected. Patient 1 and 2 were born at full term displaying normal 
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height, weight and head circumference with no reported perinatal problems. Since 2 years of age the 
weight of both patients has been consistently >97th percentile, with Patient 2 classified as severely 
obese. This has resulted in patient 2 having limited movement (awkward gait), however, neither 
sibling displays focal motor deficits of the limbs. Additionally, both siblings display a dysmorphic 
facial phenotype with low forehead and hairline, bushy eyebrows, high arched palate and dental 
malocclusion (Figure 1A). 
Psychomotor development was normal up to 36 months for patient 1 and 18 months for 
patient 2. At these points, the patients developed trunk swinging motor stereotypies and complex 
partial seizures. These seizures were characterised by loss of contact, emission of screams, 
expressions of fright and redness of the face with perilabial cyanosis. Over time the seizures became 
more frequent and additional features developed including stertorous breathing, loss of 
consciousness and sometimes generalised tonic-clonic movement or falling to the ground. The 
seizures were rapidly and completely controlled by Carbamazepine (1000 mg/day) in patient 1. 
However, for patient 2 Carbamazepine treatment provided only a temporary decrease in the 
frequency of seizures and she ultimately became unresponsive to it as well as several other 
anticonvulsants (valproate, phenobarbital, vigabatrine, clobazam, lamotrigine and topiramate). 
Currently Patient 2 has daily seizures of variable frequency (up to 4-5 episodes per day).  
An EEG performed in patient 1 displayed poorly organised background activity without slow 
and eliptiform abnormalities. In contrast, patient 2 displayed short theta widespread outbursts with 
pseudo-periodic trend at 20 months of age. During sleep these outbursts were prevalent in the left 
hemisphere of the medial temporal region. At 4 years and 2 months of age, patient 2 performed 
another EEG. In this case, background activity was well organized, with outbursts of slow waves (4/5 
Hz) sometimes preceded by small amplitude spikes in the right temporal region and spreading to 
temporal regions of the contralateral hemisphere. During sleep, the anomalies assumed the 
character of slow waves and slow spike-waves that spread from the right hemisphere to the 
contralateral side. Recorded seizures showed theta-delta waves and spikes in right temporal 
hemisphere and vertex, followed by 3 Hz slow activity spread throughout the right hemisphere. At 14 
years old patient 2 underwent EEG exams during sleep and showed diffuse epileptiform 
abnormalities (spikes) in anterior bilateral regions.  
An MRI scan of patient 1 did not identify any gross structural abnormalities. However, 
patient 2 displayed hypoplasia of the cerebellar vermis and hemispheres. Both patients have now 
been diagnosed with severe intellectual disability according to the Wechsler adult intelligence scale, 
and have also been classified with autistic spectrum disorder (DSM 5). 
Language regression occurred simultaneously with seizure onset in both patients. For patient 
1, only syllables were initially lost followed by disappearance of verbal production. Currently, the 
proband’s language skills are limited to a few isolated words, rarely spoken with communicative 
intent. Patient 1 also displays vocal tics, reduced relational capacity and autonomy, together with 
increased stereotypies and clumsiness. Patient 2 had progressive behavioural changes with a slowing 
in language acquisition, impoverished interpersonal skills and verbal communication, including 
inertia and apathy. The patient’s mother reported alternating periods of more pronounced 
symptoms, with periods in which seizures were better controlled and the child appeared to be more 
attentive and involved, but also more aggressive. 
 
Genetic analysis 
Molecular analysis of the patients was normal for karyotype (46XX) and negative for the 
presence of sub-telometric deletions. Array-CGH revealed a deletion of at least 127 Kb in 
chromosome 7q35 (hg18; Chr7:146,082,310-146,189,705). Both affected probands were 
homozygous for the deletion, while the parents were heterozygous. The unaffected male sibling did 
not carry this deletion. The exact breakpoints were mapped via PCR and direct Sanger sequencing 
revealing a 203 kb deletion (hg38; Chr7:146,711,006-146,914,175) spanning exon 2-3 of the 
CNTNAP2 gene. CNTNAP2 expression was assayed in peripheral blood and in transformed 
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lymphoblast cells, but expression levels were too low to reliably detect a signal in patient or control 
samples (data not shown (see also [12, 13]). Sequence analysis suggested that the loss of exons 2-3 
introduces a frameshift into the CNTNAP2 transcript. This frameshift produces an early stop codon at 
amino acid 39 (L39X) that would severely truncate the protein product and is likely to lead to 
nonsense mediated decay (Figure 1C). This suggests that the CNV reported in these patients results 
in complete loss of functional CASPR2 protein in the homozygous state. 
 
 
Figure 1. (A) Clinical picture of the affected probands reported in this study. Note dysmorphic facial 
phenotype, low forehead and bushy eyebrows. Photos of the patients reported in Orrico et. al. are 
included for comparison [18] (adapted from [18]) (B) Pedigree of the family showing the two affected 
siblings (filled symbols) with homozygous deletions encompassing exons 2-3 of the CNTNAP2 gene. 
The brother is unaffected (unfilled symbol) and has no detected CNV's. Parents are first cousins and 
both carry the heterozygous CNTNAP2 deletion (symbols with dots), but are phenotypically normal. 
(C) PCR gel of the mutant CNTNAP2 gene. A ~700 base pair product could be amplified from the 
**Photos removed to comply with pre-print posting policy** 
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homozygous siblings and heterozygous parent, but not from the unaffected sibling. A Sanger 
sequencing trace shows the location of the deletion breakpoint. (D) The wild type CASPR2 protein 
and functional consequences of CNTNAP2 patient mutations on the CASPR2 protein product. CASPR2 
is composed of 1331 amino acids with a number of functional domains including a signal peptide 
(SP), discoidin/neuropilin homology domain (F5/8 Type C), Laminin G domain (LamG), Epidermal 
Growth Factor like domain (EGF-like), Fibrinogen domain (Fibrinogen), Transmembrane domain 
(Transmembrane), and Protein 4.1 homologous binding domain (4.1m). The exon 2-3 deletion 
(reported herein), exon 3 deletion[16] and c3709delG mutation[14] all produce truncated proteins 
due to early stop codons. The exon 2-9 deletion[13] also produces a truncated protein product, 
however in this case it is due to an in-frame loss of amino acids 33-500. 
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Table 1. Physical, neurodevelopmental and behavioural features of patients identified with 
homozygous CNTNAP2 mutations resulting in CASPR2 deficiency disorder. 
    
Strauss et al, 
2006,   
Jackman et al, 
2009 
Zweier et al, 2009 
Orrico et al, 2001 
Watson et al, 
2014 
This study 
Patients   18 2 3 2 
Mutation 










Resulting protein I1253X del.33-500 A156X L39X 
Development 
Pregnancy NR Normal Normal Normal 
Mental retardation Severe Severe Severe Severe 
Psychomotor delay + Mild + + 
Gross motor delay + Mild + - 
Ataxic cerebral palsy NR NR + - 
Morphology 
Dysmorphic NR + Mild + 
Low forehead/hairline NR + NR + 
Arched palate NR - NR + 
Dental malocclusion NR - NR + 
Obesity NR - NR + 




(only one sib) 
Behaviour 
Autism + - - + 
Autistic features + + + + 
Motor stereotypies NR + + + 
Communicative 
impairment 
+ + + + 
Behavioural problems + + + + 
Inertia/apathy NR NR NR + 
Agression + NR NR + 
ADHD + NR restlessness - 
Epilepsy 
Seizures Yes  Yes Yes Yes 
Age onset (months) 13-20  22-30  24 20-36 









+ + + + 
Vocal tics NR NR NR + 
Limited/absent 
language 
+ + + + 
Neurological Dysplasia + + NR + 
Breathing/other 
hyperventilation NR + NR - 
apnea NR +/- (only one sib) NR - 
cyanoses NR +/- (only one sib) NR + 
loss of consciousness NR +/- (only one sib) NR + 
      
NR = Not reported 
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Herein we report two sisters with a homozygous deletion affecting the CNTNAP2 gene and a 
phenotype including dysmorphic features, severe mental retardation, early onset seizures, autism 
spectrum disorder and language impairment. Heterozygous family members carrying this deletion 
were phenotypically normal. Previously, only three other examples of homozygous loss-of-function 
CNTNAP2 mutations have been reported. A search of publicly available exome sequencing data (ExAc 
database (http://exac.broadinstitute.org/)) did not show any homozygous coding changes in 
CNTNAP2. One SNP in intron 12 (rs113545270) was reported to be homozygous in 76 of 5,077 
exomes in the ExAc database. This variant was also reported as a possible loss-of-function change for 
an alternative transcript variant of CNTNAP2; however there is little evidence that this highly 
truncated variant is expressed. Furthermore this alternative transcript has been flagged as ‘suspect’ 
by the ensemble database (http://www.ensembl.org/index.html), suggesting that this is a non-coding 
change. The first of the reported homozygous CNTNAP2 deletions consisted of an old-order Amish 
cohort with a frameshift mutation (c.3709delG) in 18 individuals resulting in the introduction of an 
early stop codon towards the C-terminus of the CASPR2 protein (I1253X) (Figure 1C)[14]. The protein 
produced from this mutation retains all the extracellular CASPR2 domains, but is no longer tethered 
to the neuronal cell membrane and is secreted, suggesting a loss of functional CASPR2 [15]. An 
unrelated consanguineous family was identified in which three members had a homozygous deletion 
of exon 3 within the CNTNAP2 locus [16]. The loss of exon 3 is predicted to introduce an early stop 
codon (A156X) due to a frameshift mutation. This is likely to result in nonsense mediated decay 
(NMD) of the RNA product and complete loss of CNTNAP2 protein in these probands (Figure 1C). 
Finally an in-frame homozygous deletion of CNTNAP2 exons 2-9 (amino acids 33-500; del.33-500) was 
reported in two siblings of another unrelated family [17]. Deletion of these amino acids is predicted 
to result in the partial loss of extracellular domains (Figure 1C). Molecular studies would be needed 
to determine if this mutant form of CASPR2 retains any functional characteristics, however the loss 
of almost half the extracellular domain of this protein is suggestive of a severe disruption of function. 
As in the family reported herein, heterozygous family members were identified in each of these three 
cases that were phenotypically normal. 
In all cases where CASPR2 deficiency was identified, individuals displayed severe intellectual 
disability and early onset of severe seizures, beginning by 13-36 months of age and often associated 
with speech/language and behavioural regression (Table 1). Most patients displayed seizures that 
were refractive to pharmacological or surgical treatments. Pharmacological intervention has only 
successfully managed seizures in 3 patients (the A156X siblings were responsive to carbamazepine 
and valproate respectively and patient 1 described herein was responsive to carbamazepine). In all 
patients, seizures were severe and frequent, with multiple episodes per day being reported in all 
cases. However, the early seizure onset observed in these patients presents difficulties in 
distinguishing between phenotypes such as speech/language impairment that could be directly due 
to CNTNAP2 mutation or secondary to seizures. For example in I1253X patients, language 
comprehension was reported to be good before seizure onset around 13-20 months, but all patients 
showed language regression from 36 months. However, in contrast, in the A156X family the male 
child did not speak or vocalise, even before seizure onset. Similarly, the del.33-500 siblings only 
developed a few isolated words. The patients we report herein (L39X) showed language regression 
occurring simultaneously with seizure onset, until speech became limited to the rare use of isolated 
words. Taken together, these families suggest that CNTNAP2 loss results in seizures that may cause 
language regression, but that it may also be affecting the development of regions of the brain 
involved in speech and language as impairments in these faculties can occur before seizure onset.  
All patients have also been reported to have some autistic characteristics. Both of the 
patients described herein are classified as autistic, with impoverished communication skills, 
communicative impairment, repetitive behaviour, and motor stereotypies. The majority of patients 
reported with the I1253X mutation were classified as autistic, displaying behavioural deterioration 
including restricted behaviours, aberrant social interactions and communicative impairment [14]. 
. CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a




Zweier et. al. noted that the del.33-500 siblings had limited communicative ability with variable 
“autistic behaviour and stereotypic movements” [13] and Watson et. al. reported that A156X siblings 
displayed obsessive compulsive behaviour, stereotypical movements and communicative and speech 
impairments [16]. Given that CNTNAP2 remains a top candidate gene with regards to the molecular 
basis of autism, these homozygous patients would be of great value for studying the links between 
autism and CNTNAP2. Thus there is a need for further in-depth phenotyping of the autistic 
characteristics of the homozygous patients in these families.  
Additional common features between the probands include dysmorphisms, focal cortical 
dysplasia, behavioural problems and psychomotor delay (Table 1). Dysmorphic features were 
reported from three of the four mutations (del.33-500, A156X and L39X). Although patient 
photographs were not available for all families, it was striking to note the facial similarities of the 
patients described herein and the del.33-500 patients, for whom photos have been published (Figure 
1)[18]. Both sets of siblings showed coarse facial features, low forehead, heavy eyebrows and large 
mouth with thick lips. In future, it will be of interest to determine if this mild dysmorphia is a 
universal characteristic of CASPR2 deficiency. 
Thus while some variability in phenotype remains, it is clear that homozygous loss of 
CNTNAP2 results in a syndromic disorder characterised by severe intellectual disability, early-onset 
drug-resistant epilepsy, reduced or absent language, communicative impairments and autistic 
phenotypes. To further refine the diagnostic criteria for CASPR2 deficiency disorder (CDD) it will be 
essential to identify novel patients carrying homozygous CNTNAP2 mutations by screening cohorts 
showing core syndromic phenotypes, together with a more detailed phenotypic analysis of existing 
and novel patients. Furthermore, although the mutations discussed above are predicted to result in a 
loss of CASPR2 function, cell based and molecular assays will be critical to determine which 
mutations represent a full vs. partial loss of CNTNAP2 function. This is particularly relevant for 
mutations such as del.33-500 or I1253X where truncated forms of the protein, retaining some 
functional domains, are predicted to be expressed. Determining which mutations represent a true 
loss of function together with increased phenotypic analysis will be of great value in refining the 
phenotype associated with CASPR2 deficiency disorder, and in understanding the contribution of 
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